^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PTPRD mutation

    i
    Other names: Protein-Tyrosine Phosphatase Delta, Rceptor-Type Tyrosine-Protein Phosphatase Delta, Protein Tyrosine Phosphatase, Receptor Type, Delta Polypeptide, R-PTP-Delta, Receptor-Type Tyrosine-Protein Phosphatase Delta, PTPRD, Protein Tyrosine Phosphatase Receptor Type D
    Entrez ID:
    5789
    Related biomarkers:
    Mutation
    Others
    1year
    PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer. (PubMed, Aging (Albany NY))
    Our study suggested that PTPRD mutations could serve as a predictive biomarker for the sensitivity to ICIs treatment and PFS and OS in advanced NSCLC with ICIs. Our systematic nomograms showed great potential value in clinical application to predict the PFS and OS for advanced NSCLC patients with ICIs.
    Journal • Tumor mutational burden • IO biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • PTPRD (Protein tyrosine phosphatase receptor type D)
    |
    PTPRD mutation
    1year
    A Case Report of Adult Rhabdomyosarcoma Harboring a Novel PTPRD Mutation and Concurrent DICER1 Mutation (CAP 2023)
    Our patient’s composite gene signature, recurrent rhabdomyosarcoma with unusual immunophenotype, and metastases with neuronal/neuroblastic elements suggest a closer genetic link of MEM to adult rhabdomyosarcoma. This association supports further research into the role PTPRD mutation may play in adult sarcomas and its implication for the diagnosis, tumor behavior, prognosis, and treatment of adult rhabdomyosarcoma.
    Clinical
    |
    PTPRD (Protein tyrosine phosphatase receptor type D) • DICER1 (Dicer 1 Ribonuclease III) • MYOD1 (Myogenic Differentiation 1)
    |
    PTPRD mutation
    over1year
    Surfaceome of TP53-Mutant NSCLC Reveals a Distinct Subtype with Immunotherapy Vulnerability, Characterized by Co-occurring PTPRD Mutant (IASLC-WCLC 2023)
    PTPRD mutation could derive active immunoediting via cGAS-STING pathway and potentiate ICB therapy in TP53-mutant NSCLC. Targeting PTPRD might transform the immune tolerance status in TP53-mutant NSCLC with wild type PTPRD.
    Tumor mutational burden • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTPRD (Protein tyrosine phosphatase receptor type D) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IFNB1 (Interferon Beta 1)
    |
    TP53 mutation • PTPRD mutation
    almost2years
    Genetic and Prognostic Analysis in Blastoid and Pleomorphic Mantle Cell Lymphoma: A Multicenter Analysis in China (ASH 2022)
    First-line high dose cytarabine exposure obtained survival benefits in these population, and BTKi-combined treatment in front-line had somewhat improvement in survival with no significant difference in statistic. In conclusion, B/P MCL have inferior outcomes and distinct genomic profile, patients with POD12 display a distinct mutation profile and worst prognosis, new therapeutic drugs and clinical trials need to be further explored in B/P MCL.
    Clinical
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • FAT1 (FAT atypical cadherin 1) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • ATM mutation • CDKN2A mutation • KMT2D mutation • PTPRD mutation
    |
    cytarabine
    2years
    PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types. (PubMed, Front Immunol)
    Based on the risk score of the model, patients in the low-risk group showed a better mOS than those in the high-risk group (mOS: 2.75 vs 1.08 years, HR = 0.567, 95%CI: 0.492-0.654; P < 0.001). PTPRD/PTPRT mutations may be a potential biomarker for predicting ICI treatment responsiveness in multiple cancer types.
    Journal • Checkpoint inhibition • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • PTPRT (Protein tyrosine phosphatase receptor type T)
    |
    PTPRD mutation • PTPRT mutation
    2years
    Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma. (PubMed, Front Mol Biosci)
    Further research found that CARD11 and PTPRD mutations were significantly associated with more tumor-infiltrated immune cells in melanoma samples. For the first time, we have shown that PHS can independently and effectively predict the ICI therapy outcome in metastatic melanoma, which once validated by larger research, may help the decision-making process in melanoma.
    Journal • Checkpoint inhibition • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TERT (Telomerase Reverse Transcriptase) • BAP1 (BRCA1 Associated Protein 1) • KMT2D (Lysine Methyltransferase 2D) • CARD11 (Caspase Recruitment Domain Family Member 11) • PTPRD (Protein tyrosine phosphatase receptor type D) • PTPRT (Protein tyrosine phosphatase receptor type T)
    |
    KMT2D mutation • BAP1 mutation • TERT mutation • PTPRD mutation
    over2years
    An integrative prognostic and immune analysis of PTPRD in cancer. (PubMed, Math Biosci Eng)
    Functional enrichment analysis demonstrated that a variety of GO biological processes and KEGG pathways associated with PTPRD were involved in the therapeutic mechanisms. These results revealed that PTPRD might function as a biomarker for prognosis and immune infiltration in cancers, throwing new light on cancer therapeutics.
    Journal • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • PTPRD (Protein tyrosine phosphatase receptor type D)
    |
    TMB-H • PTPRD mutation
    3years
    Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. (PubMed, BMC Med)
    Tissue or ctDNA PTPRD phosphatase domain deleterious mutations might function as a both prognostic and predictive biomarker predicting clinical outcomes of ICIs in ns-NSCLC patients, independent on TMB or PD-L1 expression.
    Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    TMB (Tumor Mutational Burden) • PTPRD (Protein tyrosine phosphatase receptor type D)
    |
    PD-L1 expression • PTPRD mutation
    over3years
    Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing. (PubMed, Lung Cancer)
    These results explain PSGTs harbor distinct driver features of MAML2 or MYB rearrangement, accompanied with wide mutational diversity with very low rate of somatic mutation. Several important pathways, including the NOTCH and PI3K pathways, and chromatin remodeling could be targeted to improve the survival in patients with ACC.
    Journal • Next-generation sequencing • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • FGFR1 (Fibroblast growth factor receptor 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • PD-1 (Programmed cell death 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • FLT1 (Fms-related tyrosine kinase 1) • RBM10 (RNA Binding Motif Protein 10) • PTPRD (Protein tyrosine phosphatase receptor type D) • NOTCH4 (Notch 4) • INPP4B (Inositol polyphosphate-4-phosphatase type II B) • CCND2 (Cyclin D2) • FOXP1 (Forkhead Box P1) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
    |
    ASXL1 mutation • FGFR1 mutation • HRAS mutation • PTPRD mutation
    over3years
    Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades. (PubMed, Front Oncol)
    This work suggested that PTPRD/PTPRT mutation might be a potential positive predictor for ICBs in NSCLC. These results need to be further confirmed in future.
    Clinical • Clinical data • Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • JAK1 (Janus Kinase 1) • PTPRT (Protein tyrosine phosphatase receptor type T) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    PTPRD mutation • PTPRT mutation
    over3years
    Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA. (PubMed, Esophagus)
    These findings may facilitate future precision medicine approaches based on genomic profiling in ESCC and EAC.
    Clinical • Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KMT2D (Lysine Methyltransferase 2D) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • EP300 (E1A binding protein p300) • PTPRD (Protein tyrosine phosphatase receptor type D) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • WRN (WRN RecQ Like Helicase)
    |
    TP53 mutation • PTPRD mutation
    almost4years
    [VIRTUAL] Clinicopathologic Characteristics and Outcomes of East Asian Patients With Non-Small-Cell Lung Cancer and FLT3 Mutations (IASLC-WCLC 2020)
    TP53, KEAP1, NTRK3 and PTPRD gene accompanied may have less correlation with FLT3 mutation in NSCLC patients. Analysis of FLT3 mutations shows promise as a way to refine individual patients with NSCLC, and provides more insight into effective treatment strategies for patients with FLT3 mutations.
    Clinical
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • KEAP1 (Kelch Like ECH Associated Protein 1) • PTPRD (Protein tyrosine phosphatase receptor type D)
    |
    TP53 mutation • FLT3 mutation • KEAP1 mutation • PTPRD mutation
    over4years
    [VIRTUAL] Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer. (ASCO 2020)
    "Molecular subtypes defined by ASCL1 and NeuroD1 encompass molecular characteristics that may predict patient outcomes. Further investigation is needed to delineate the underlying biological differences among the various subtypes to help define therapeutic vulnerabilities of each subtype of SCLC. Completion of IHC for ASCL1, NeuroD1 and additional key transcription factors POU2F3 and YAP1 are in progress for the entire cohort."
    Clinical data • Clinical
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • CCND1 (Cyclin D1) • PALB2 (Partner and localizer of BRCA2) • KMT2D (Lysine Methyltransferase 2D) • BIRC3 (Baculoviral IAP repeat containing 3) • FAT1 (FAT atypical cadherin 1) • FLT1 (Fms-related tyrosine kinase 1) • ATR (Ataxia telangiectasia and Rad3-related protein) • YAP1 (Yes associated protein 1) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • EP300 (E1A binding protein p300)
    |
    KIT mutation • PALB2 mutation • KMT2D mutation • PTPRD mutation
    |
    MSK-IMPACT
    over4years
    [VIRTUAL] PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). (ASCO 2020)
    Our results suggest that PTPRD/PTPRT mutation is associated with better PFS and OS in NSCLC patients receiving ICIs by increasing immune-related gene signatures. The role of PTPRD/PTPRT in immunotherapy is needed to be further studied. Research Funding: None
    Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • PTPRT (Protein tyrosine phosphatase receptor type T)
    |
    PTPRD mutation